What are the ACVC Biomarker Talks?
This series was designed by course directors Christian Müller and Nicholas Mills, chair and co-chair of the ACVC Study Group on Biomarkers.
The talks, in a nutshell:
- Live and interactive online events covering each topic in the biomarker field;
- Each talk will be moderated by Christian Mueller and Nicholas Mills, and presented by one expert;
- Each talk will last for 30 minutes and include a 15-20 minute state-of-the-art presentation and 10-15 minute discussion with the audience;
- The on-demand video will be available 24 hours after the live event.
Watch Season 2 (2023)
| Dates | Title | Links | Presented by |
| 26 Avril 2023 | High sensitivity cardiac troponin in stable ASCVD | David Morrow | |
| 31 May 2023 | How to use cardiac troponin T or cardiac troponin I in noncardiac surgery | Christian Puelacher | |
| 21 June 2023 | Troponin T and I: back to basics | Alma Mingels |
|
| 25 September 2023 | Cardiac biomarkers in pulmonary embolism | Evangelos Giannitsis | |
| 7 November 2023 | Cardiac Biomarkers post PCI | Allan Jaffe |
Watch season 1 (2022)
About the ACVC Study Group on Biomarkers
Background
The ACVC Study Group on Biomarkers was established by Kristian Thygesen (DK) in 2005 with the intention of creating a support group for the Global Task Force for the Definition of Myocardial Infarction (later called Universal Definition of Myocardial Infarction - UDMI).
In addition to supporting the UDMI, this group became successful and independent and now focuses on the proper clinical application of cardiac biomarkers including troponins, natriuretic peptides, and inflammatory and thrombotic markers in acute cardiac care.
Objectives
- disseminating knowledge about the proper clinical application of cardiac biomarkers in acute cardiovascular care;
- advising on the appropriate application of biomarkers in cardiovascular research;
- creating recommendations/guidelines for implementation of cardiac biomarkers in acute cardiac care; and
- being a counselling source for authorities regarding the appropriate clinical use of cardiac biomarkers.
Our mission: To reduce the burden of cardiovascular disease.